Cutaneous pseudolymphoma associated with a TNF-alpha inhibitor treatment: etanercept.
Guis
Sandrine
S
Schiano de Colella
Jean-Marc
JM
Bonnet
Nathalie
N
Andrac-Meyer
Lucille
L
Balandraud
Nathalie
N
Mattei
Jean-Pierre
JP
Franck
Bernard
B
Roudier
Chantal
C
Roudier
Jean
J
Berbis
Phillippe
P
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D019310:Pseudolymphoma / Q000139:chemically induced*; D018124:Receptors, Tumor Necrosis Factor; D012871:Skin Diseases / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept